BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33171190)

  • 1. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
    Li X; Ou X; Luo G; Ou X; Xie Y; Ying M; Qu W; Zuo H; Qi X; Wang Y; Liu Z; Zhu L
    Toxicol Appl Pharmacol; 2020 Dec; 409():115332. PubMed ID: 33171190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
    Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance-associated protein 2 is involved in the efflux of Aconitum alkaloids determined by MRP2-MDCKII cells.
    Dai P; Zhu L; Yang X; Zhao M; Shi J; Wang Y; Lu L; Liu Z
    Life Sci; 2015 Apr; 127():66-72. PubMed ID: 25744397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway.
    Wu JJ; Zhu YF; Guo ZZ; Lou YM; He SG; Guan Y; Zhu LJ; Liu ZQ; Lu LL; Liu L
    Phytomedicine; 2018 May; 44():87-97. PubMed ID: 29277460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
    Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
    Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Mediate the Disposition of Leonurine-10-O-β-glucuronide.
    Li X; Xie Y; Qu W; Ou X; Ou X; Wang C; Qi X; Wang Y; Liu Z; Zhu L
    Curr Drug Metab; 2020; 21(13):1060-1067. PubMed ID: 33198612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
    Chisaki I; Kobayashi M; Itagaki S; Hirano T; Iseki K
    Biochim Biophys Acta; 2009 Nov; 1788(11):2396-403. PubMed ID: 19728987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdr1a plays a crucial role in regulating the analgesic effect and toxicity of aconitine by altering its pharmacokinetic characteristics.
    Zhu L; Wu J; Zhao M; Song W; Qi X; Wang Y; Lu L; Liu Z
    Toxicol Appl Pharmacol; 2017 Apr; 320():32-39. PubMed ID: 28193520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
    Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
    Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
    Geyer J; Gavrilova O; Petzinger E
    J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.